Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + toripalimab in elderly locally advanced nasopharyngeal carcinoma
ChiCTR2100042794Phase 2Recruiting
- Sponsor
- Medical Ethics Committee of Jiangxi Cancer Hospital
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Medical Ethics Committee of Jiangxi Cancer Hospital. Primary endpoint: Progression-free survival (PFS). Started Feb 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100042794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042794.